Schering-Plough’s Vytorin “Permanently Broken,” Analyst Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ENHANCE data prompts Avandia-like scramble.
You may also be interested in...
Schering’s Organon Grab Made Merck's Merger Magic Happen
Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.
Schering’s Organon Grab Made Merck's Merger Magic Happen
Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.